View Older Stories View More Recent Stories
-
InspireMD appoints Dan Dearen to board of directors
-
InspireMD Announces the Appointment of Dan Dearen to its Board of Directors
-
InspireMD Reports Second Quarter 2025 Financial Results
-
InspireMD raises $58 million through equity placement and warrant exercise
-
InspireMD appoints Raymond W. Cohen to board of directors
-
InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors
-
InspireMD Announces Combined Financings of $58 Million
-
InspireMD launches CGuard Prime carotid stent system in US market
-
InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
-
InspireMD (NSPR) Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of Stroke
-
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke
-
InspireMD (NSPR) Announces CE Mark Approval for CGuard Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
-
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
-
InspireMD Reports First Quarter 2025 Financial Results
-
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results
-
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
-
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
InspireMD (NSPR) Announces CFO Change
-
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025
-
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
-
InspireMD (NSPR)Appoints Scott R. Ward to its Board
-
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
-
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update
-
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
-
InspireMD (NSPR) Announces Approval of IDE Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
-
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
-
InspireMD (NSPR) Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
-
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
-
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
-
InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment
-
InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
-
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
-
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update
-
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
-
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
-
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
-
InspireMD (NSPR) Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
-
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
-
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
-
InspireMD (NSPR) Issued US Patent Covering SwitchGuard Neuroprotection System
-
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
-
InspireMD (NSPR) Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
-
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
-
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
-
InspireMD (NSPR) Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. IDE Clinical Trial at VIVA23
-
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
